LivingGLP1
Study S000366

Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

ClinicalTrials.gov record

Registration

Registration
NCT06351748
Acronym
SCHOLAR
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
34238
Start
2024-01-02
Primary completion
2024-03-29
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:Semaglutide
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1296-3151

Registered primary outcomes

  • Change in Haemoglobin A1c (HbA1c) level [From baseline (3 months prior to or on the index date) to 6 months]
  • Change in HbA1c level [From baseline (3 months prior to or on the index date) to 6 months]
  • Proportion of participants achieving HbA1c less than (<) 7.0% [At 6 months]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0012141Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.
Wang S, Diabetes therapy : research, treatment and education of diabetes and related disorders
2026Nonrandomized studyPMID 42803912DOIcites ClinicalTrials.gov:NCT06351748; registry reference DERIVED:42803912
R0014946Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.
Wang S, Diabetes therapy : research, treatment and education of diabetes and related disorders
2026Nonrandomized studyPMID 41848818DOIcites ClinicalTrials.gov:NCT06351748; registry reference DERIVED:41848818
R00375421798-P: Combined Semaglutide and Sodium–Glucose Cotransporter 2 Inhibitors in Real-World Clinical Practice in China: Scholar Post Hoc Analysis
SHANSHAN WANG, Diabetes
2026Nonrandomized studyDOIcites ClinicalTrials.gov:NCT06351748